1.02
-1.92%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Brii Biosciences
Its shares trade on HKEX under the ticker 2137.HK. It has been listed since 13 July 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥18.1m and a net loss of CN¥216.9m. At that date it held total assets of CN¥2.36bn and shareholders' equity of CN¥2.38bn.
Brii Biosciences Ltd. engages in advancing therapies for significant infectious diseases and other illnesses which have significant public health burdens. The company is headquartered in Beijing, Beijing. The company went IPO on 2021-07-13. The Company’s products are applied in infectious diseases, such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens. The firm is also developing therapies for COVID-19 and other diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Jul 2021
- Employees
- 133
- Website
- briibio.com ↗
Leadership
Pay as last reported
- Dr. Zhi HongExecutive Chairman of the Board, Chief Executive Officer, since 2018CN¥65.4m
- Dr. Ankang LiChief Financial Officer, Executive Director, Joint Company Secretary, Chief Strategy Officer, Chief Executive Officer of TSB, since 2020
- Dr. Karen NeuendorffChief People Officer, Head of Human Resources
- Mr. Rico LiangSenior Vice President, General Manager, Greater China
- Dr. David MargolisSenior Vice President, Head of Infectious Diseases Therapy Area
- Mr. Coy StoutSenior Vice President, Head of U.S. Market Access and Patient Advocacy
- Dr. Lianhong XuSenior Vice President, Head of Medicinal Chemistry
- Mr. Li YanChief Medical Officer
- Dr. Qing ZhuHead of China Research and Development
- Ms. Wing Tsz HoJoint Company Secretary
- Mr. Robert NelsenNon-Executive Director
- Mr. Gregg AltonIndependent Non-Executive DirectorCN¥129,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Brii Biosciences Ltd. employs 133 full-time employees in Beijing, China.
- The company focuses on infectious diseases like HBV, HIV, and MDR/XDR gram-negative infections.
- Brii Biosciences develops therapies for significant public health burdens including CNS diseases and COVID-19.
Weaknesses
- Brii Biosciences Ltd. has a small workforce of 133 employees in Beijing, China.
- The company's product portfolio is limited to infectious diseases and CNS diseases.
- Brii Biosciences has only one IPO date, 13 July 2021, for its public listing.
Opportunities
- Brii Biosciences can expand its therapies for MDR/XDR gram-negative infections in China.
- The company can develop more therapies for CNS diseases in the Health Care sector.
- Brii Biosciences may grow its product line for infectious diseases like HBV and HIV.
Threats
- Brii Biosciences faces competition from other biotechnology firms in China.
- The company's focus on infectious diseases could be affected by new public health policies.
- Brii Biosciences must navigate regulatory challenges in the Health Care sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.